EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey
Open accessAbstract
INTRODUCTION: The efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer (NSCLC) patients necessitates accurate, timely testing. Although EGFR mutation testing has been adopted by many laboratories in Asia, data are lacking on the proportion of NSCLC patients tested in each country, and the most commonly used testing methods. METHODS: A retrospective survey of records from NSCLC patients tested for EGFR mutations during 2011 was conducted in 11 Asian Pacific countries at 40 sites that routinely performed EGFR mutation testing during that period. Patient records were used to complete an online questionnaire at each site. RESULTS: Of the 22,193 NSCLC patient records surveyed, 31.8% (95% confidence interval: 31.2%-32.5%) were tested for EGFR mutations. The rate of EGFR mutation positivity was 39.6% among the 10,687 cases tested. The majority of samples were biopsy and/or cytology samples (71.4%). DNA sequencing was the most commonly used testing method accounting for 40% and 32.5% of tissue and cytology samples, respectively. A pathology report was available only to 60.0% of the sites, and 47.5% were not members of a Quality Assurance Scheme. CONCLUSIONS: In 2011, EGFR mutation testing practices varied widely across Asia. These data provide a reference platform from which to improve the molecular diagnosis of NSCLC, and EGFR mutation testing in particular, in Asia.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The prevalence of EGFR mutations varies by ethnicity, from 5-10% in white patients to 60-70% in never-smoking Asian patients with adenocarcinoma.
“For example, the prevalence of EGFR mutations ranges from between 5% and 10% in whites to between 60% and 70% in neversmoking Asian patients with adenocarcinoma”
In large population-based testing experiences, 70-85% of tested samples were core needle biopsies, fine-needle aspirates, or fluid specimens.
“large population-based testing experiences have reported that 70% to 85% of tested samples include core needle biopsy specimens, fine-needle aspiration samples, and fluid specimens.4,40”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261 · see citing works
Self-citationGefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525 · see citing works
Self-citationRosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489 · see citing works
Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090 · see citing works
Self-citationZhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081 · see citing works
Self-citationSomatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681 · see citing works
Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Dacic, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J.-S., Squire, J., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318290868f · Cited by 1,280 · see citing works
New driver mutations in non-small-cell lung cancer
Pao, W. J., & Girard, N. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70087-5 · Cited by 1,172 · see citing works
New driver mutations in non-small-cell lung cancer
Tanoue, L. T. (2012) · Yearbook of Pulmonary Disease · doi:10.1016/j.ypdi.2012.01.036 · Cited by 833 · see citing works
Dearden, S., Stevens, J., Wu, Y.-L., & Blowers, D. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt205 · Cited by 646 · see citing works
Mitsudomi, T., & Yatabe, Y. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00607.x · Cited by 606 · see citing works
Self-citationTokumo, M., Toyooka, S., Kiura, K., Shigematsu, H., Tomii, K., Aoe, M., Ichimura, K., Tsuda, T., Yano, M., Tsukuda, K., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.1167.11.3 · Cited by 489 · see citing works
Self-citationLindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Đačić, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J., Squire, J. A., et al. (2013) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0720-oa · Cited by 424 · see citing works
Ellison, G., Zhu, G., Moulis, A., Dearden, S., Speake, G., & McCormack, R. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2012-201194 · Cited by 301 · see citing works
Self-citationConsensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop
Pirker, R., Herth, F. J. F., Kerr, K. M., Filipits, M., Tarón, M., Gandara, D. R., Hirsch, F. R., Grunenwald, D. H., Popper, H., Smit, E. F., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f1c8de · Cited by 283 · see citing works
Self-citationYoshida, K., Yatabe, Y., Park, J. Y., Shimizu, J., Horio, Y., Matsuo, K., Kosaka, T., Mitsudomi, T., & Hida, T. (2007) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(15)30013-7 · Cited by 165 · see citing works
Self-citationNational survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China
Xue, C., Hu, Z., Jiang, W., et al. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.04.014 · Cited by 114 · see citing works
Goto, K., Satouchi, M., Ishii, G., Nishio, K., Hagiwara, K., Mitsudomi, T., Whiteley, J. L., Donald, E. L., McCormack, R., & Todo, T. (2012) · Annals of Oncology · doi:10.1093/annonc/mds121 · Cited by 103 · see citing works
Self-citationRecommendations for mutational analysis of EGFR in lung carcinoma.
Marchetti, A., Normanno, N., Pinto, C., et al. (2010) · PubMed · Cited by 37 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Dong, Z.-Y., Zhang, J.-T., Liu, S.-Y., Su, J., Zhang, C., Xie, Z., Zhou, Q., Tu, H.-Y., Xu, C.-R., Yan, L.-X., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1356145 · Cited by 440 · see citing works
Kobayashi, Y., & Mitsudomi, T. (2016) · Cancer Science · doi:10.1111/cas.12996 · Cited by 413 · see citing works
Tan, D. S. W., Yom, S. S., Tsao, M. S., Pass, H. I., Kelly, K., Peled, N., Yung, R. C., Wistuba, I. I., Yatabe, Y., Unger, M., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.05.008 · Cited by 201 · see citing works
Self-citationTAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations
Hasako, S., Terasaka, M., Abe, N., Uno, T., Ohsawa, H., Hashimoto, A., Fujita, R., Tanaka, K., Okayama, T., Wadhwa, R., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1206 · Cited by 88 · see citing works
Banno, E., Togashi, Y., Nakamura, Y., Chiba, M., Kobayashi, Y., Hayashi, H., Terashima, M., de Velasco, M. A., Sakai, K., Fujita, Y., et al. (2016) · Cancer Science · doi:10.1111/cas.12980 · Cited by 87 · see citing works
Cheng, Y. Y., Rath, E. M., Linton, A., Yuen, M. L., Takahashi, K., & Lee, K. (2020) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s186843 · Cited by 31 · see citing works
- Authors
- Yatabe, Y., Kerr, K. M., Utomo, A., Rajadurai, P., Tran, V. K., Du, X., Chou, T.-Y., Enriquez, M. L. D., Lee, G. K., Iqbal, J., Shuangshoti, S., Chung, J.-H., Hagiwara, K., Liang, Z., Normanno, N., Park, K., Toyooka, S., Tsai, C.-M., Waring, P., Zhang, L., McCormack, R., Ratcliffe, M., Itoh, Y., Sugeno, M., & Mok, T.
- Affiliations
- Monash University Malaysia (MY)
- Fudan University (CN)
- Taipei Veterans General Hospital (TW)
- St. Luke's Medical Center (PH)
- National Cancer Center (KR)
- Singapore General Hospital (SG)
- Seoul National University Bundang Hospital (KR)
- Saitama Medical University (JP)
- Peking Union Medical College Hospital (CN)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- Samsung Medical Center (KR)
- Okayama University (JP)
- Sun Yat-sen University Cancer Center (CN)
- AstraZeneca (United Kingdom) (GB)
- AstraZeneca (Japan) (JP)
- Chinese University of Hong Kong (HK)
- Corresponding author
- Yatabe, Yasushi
- ORCID
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2015-03
- Volume
- 10
- Issue
- 3
- Pages
- 438-445
- ISSN
- 1556-0864 (ISSN-L)
- PMC
- PMC4342317
- OpenAlex
- W2077848542
- Cited by
- 182
- References
- 19
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 19 · 2023: 21 · 2022: 23 · 2021: 16 · 2020: 22 · 2019: 20 · 2018: 21 · 2017: 13 · 2016: 10 · 2015: 8
- FWCI
- 8.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Thoracic Oncology (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
- Funders
- AstraZeneca
- Japan Society for the Promotion of Science (25293090)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- EGFR mutation testing, non-small cell lung cancer, EGFR tyrosine kinase inhibitors, Asia-Pacific region, diagnostic practices, DNA sequencing, pathology reports, quality assurance, molecular diagnosis
- MeSH terms
- Adenocarcinoma, Asia, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, DNA Mutational Analysis, DNA, Neoplasm, Female, Follow-Up Studies, Humans, Lung Neoplasms, Male, Mutation, Neoplasm Staging, Pacific Islands, Prognosis, Reagent Kits, Diagnostic, Retrospective Studies, Polymerase Chain Reaction, Databases, Factual, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
